Market Closed -
Nasdaq
03:59:30 2024-07-12 pm EDT
5-day change
1st Jan Change
1.43
USD
0.00%
+5.15%
+110.29%
Presentation Operator MessageOperator (Operator)Good morning. My name is Marliese, and I will ...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer
Jun. 24
CI
IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial
Jun. 05
CI
Imunon, Inc. Announces CFO Changes, Effective from June 1, 2024
May. 20
CI
Transcript : Imunon, Inc., Q1 2024 Earnings Call, May 13, 2024
May. 13
IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
May. 13
CI
Imunon, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 13
CI
IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024
May. 08
CI
IMUNON, Inc. Appoints Stacy R. Lindborg as President, Effective May 13, 2024
May. 08
CI
Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine
Apr. 18
MT
Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine
Apr. 18
DJ
Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101
Apr. 18
CI
HC Wainwright Adjust Price Target on Imunon to $13 From $12, Keeps Buy Rating
Apr. 01
MT
Top Midday Gainers
Mar. 28
MT
Transcript : Imunon, Inc., Q4 2023 Earnings Call, Mar 28, 2024
Mar. 28
Imunon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 28
CI
North American Morning Briefing : Stocks Set for -2-
Mar. 28
DJ
Imunon, Inc. Files Ind Application to Begin Human Testing of Imnn-101
Mar. 13
CI
IMUNON Names Executive Chairman as Temporary Head Following Resignation of CEO Corinne Le Goff
Mar. 13
MT
Imunon, Inc. Announces Executive Changes
Mar. 12
CI
Imunon, Inc. Announces Resignation of Corinne Le Goff as Chief Executive Officer, Effective March 15, 2024
Mar. 12
CI
Imunon, Inc. Appoints Sebastien Hazard as Executive Vice President and Chief Medical Officer
Dec. 11
CI
Transcript : Imunon, Inc., Q3 2023 Earnings Call, Nov 14, 2023
Nov. 14
Imunon, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 14
CI
Imunon, Inc. Provides an Update on Its Clinical Development Programs with Imnn-001 (Formerly Gen-1), A Dna-Based Interleukin-12 (Il-12) Immunotherapy in Phase 2 Clinical Development for the Treatment of First-Line Locally Advanced Ovarian Cancer
Nov. 14
CI
IMUNON, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMUNON-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
23-10-18
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the bodyâs natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunonâs DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.
More about the company
Last Close Price
1.43
USD
Average target price
10
USD
Spread / Average Target
+599.30%
Consensus
1st Jan change
Capi.
+110.29% 13.44M +20.12% 126B +25.25% 119B +25.56% 27.95B -19.51% 20.5B -14.36% 17.12B -15.63% 16.1B -46.67% 14.97B +11.89% 14.84B +57.74% 14.38B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1